Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Short Bowel Syndrome
- Main trialPhase 2/3
- “The objective of this clinical study is to evaluate the efficacy and safety of NTRA-9620 compared with placebo in pediatric subjects (aged 28 weeks postmenstrual age to 52 weeks old) with SBS following surgical resection”In the company’s words, NCT02865122 on ClinicalTrials.gov
Other drugs for Short Bowel Syndrome
- TeduglutideTakeda · Phase 3
- ApraglutideVectivBio AG · Phase 3
- GlepaglutideZealand Pharma · Phase 3
- PJ009Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 3
- CrofelemerNapo Pharmaceuticals, Inc. · Phase 2
- FT1Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Terminated | 22 Mar 2018 | Safety and Efficacy Study in Infant With SBS |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026